vs
EverCommerce Inc.（EVCM）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是EverCommerce Inc.的1.3倍（$197.9M vs $151.2M），REPLIGEN CORP净利率更高（6.7% vs 4.0%，领先2.7%），REPLIGEN CORP同比增速更快（13.6% vs 5.2%），EverCommerce Inc.自由现金流更多（$21.0M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 4.7%）
EverCommerce Inc.是面向服务类中小企业的领先集成SaaS解决方案提供商，核心市场覆盖北美及部分全球区域，产品线包含业务管理、支付处理、客户互动、营销工具等，服务家庭服务、健康康养、健身等多个细分领域。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
EVCM vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.3倍
$151.2M
营收增速更快
RGEN
高出8.5%
5.2%
净利率更高
RGEN
高出2.7%
4.0%
自由现金流更多
EVCM
多$3.4M
$17.6M
两年增速更快
RGEN
近两年复合增速
4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.2M | $197.9M |
| 净利润 | $6.0M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 8.8% | 9.0% |
| 净利率 | 4.0% | 6.7% |
| 营收同比 | 5.2% | 13.6% |
| 净利润同比 | 149.4% | 143.9% |
| 每股收益（稀释后） | $0.04 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVCMRGEN
| Q4 25 | $151.2M | $197.9M | ||
| Q3 25 | $147.5M | $188.8M | ||
| Q2 25 | $148.0M | $182.4M | ||
| Q1 25 | $142.3M | $169.2M | ||
| Q4 24 | $143.7M | $174.1M | ||
| Q3 24 | $140.1M | $154.9M | ||
| Q2 24 | $140.5M | $154.1M | ||
| Q1 24 | $137.9M | $151.3M |
净利润EVCMRGEN
| Q4 25 | $6.0M | $13.3M | ||
| Q3 25 | $11.1M | $14.9M | ||
| Q2 25 | $8.2M | $14.9M | ||
| Q1 25 | $-7.7M | $5.8M | ||
| Q4 24 | $-12.2M | $-30.3M | ||
| Q3 24 | $-9.2M | $-654.0K | ||
| Q2 24 | $-3.4M | $3.3M | ||
| Q1 24 | $-16.3M | $2.1M |
毛利率EVCMRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率EVCMRGEN
| Q4 25 | 8.8% | 9.0% | ||
| Q3 25 | 10.8% | 8.9% | ||
| Q2 25 | 10.7% | 7.6% | ||
| Q1 25 | 10.0% | 3.9% | ||
| Q4 24 | 8.8% | -17.7% | ||
| Q3 24 | 7.2% | -5.1% | ||
| Q2 24 | 5.5% | 1.0% | ||
| Q1 24 | -3.1% | 1.3% |
净利率EVCMRGEN
| Q4 25 | 4.0% | 6.7% | ||
| Q3 25 | 7.5% | 7.9% | ||
| Q2 25 | 5.5% | 8.2% | ||
| Q1 25 | -5.4% | 3.4% | ||
| Q4 24 | -8.5% | -17.4% | ||
| Q3 24 | -6.5% | -0.4% | ||
| Q2 24 | -2.4% | 2.2% | ||
| Q1 24 | -11.8% | 1.4% |
每股收益（稀释后）EVCMRGEN
| Q4 25 | $0.04 | $0.24 | ||
| Q3 25 | $0.06 | $0.26 | ||
| Q2 25 | $0.04 | $0.26 | ||
| Q1 25 | $-0.04 | $0.10 | ||
| Q4 24 | $-0.06 | $-0.55 | ||
| Q3 24 | $-0.05 | $-0.01 | ||
| Q2 24 | $-0.02 | $0.06 | ||
| Q1 24 | $-0.09 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.7M | $767.6M |
| 总债务越低越好 | $523.4M | $542.2M |
| 股东权益账面价值 | $716.9M | $2.1B |
| 总资产 | $1.4B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.73× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资EVCMRGEN
| Q4 25 | $129.7M | $767.6M | ||
| Q3 25 | $106.9M | $748.7M | ||
| Q2 25 | $151.1M | $708.9M | ||
| Q1 25 | $148.4M | $697.2M | ||
| Q4 24 | $135.8M | $757.4M | ||
| Q3 24 | $101.6M | $784.0M | ||
| Q2 24 | $86.7M | $809.1M | ||
| Q1 24 | $90.0M | $780.6M |
总债务EVCMRGEN
| Q4 25 | $523.4M | $542.2M | ||
| Q3 25 | $524.6M | $537.9M | ||
| Q2 25 | $525.8M | — | ||
| Q1 25 | $526.9M | — | ||
| Q4 24 | $527.9M | $525.6M | ||
| Q3 24 | $529.0M | — | ||
| Q2 24 | $530.1M | — | ||
| Q1 24 | $531.1M | — |
股东权益EVCMRGEN
| Q4 25 | $716.9M | $2.1B | ||
| Q3 25 | $728.5M | $2.1B | ||
| Q2 25 | $744.0M | $2.1B | ||
| Q1 25 | $739.6M | $2.0B | ||
| Q4 24 | $750.8M | $2.0B | ||
| Q3 24 | $770.7M | $2.0B | ||
| Q2 24 | $784.1M | $2.0B | ||
| Q1 24 | $800.7M | $2.0B |
总资产EVCMRGEN
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.4B | $2.9B | ||
| Q1 25 | $1.4B | $2.9B | ||
| Q4 24 | $1.4B | $2.8B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.9B | ||
| Q1 24 | $1.5B | $2.8B |
负债/权益比EVCMRGEN
| Q4 25 | 0.73× | 0.26× | ||
| Q3 25 | 0.72× | 0.26× | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 0.70× | 0.27× | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $21.0M | $17.6M |
| 自由现金流率自由现金流/营收 | 13.9% | 8.9% |
| 资本支出强度资本支出/营收 | 0.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 3.52× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $109.2M | $93.9M |
8季度趋势，按日历期对齐
经营现金流EVCMRGEN
| Q4 25 | $21.3M | $25.7M | ||
| Q3 25 | $32.5M | $48.1M | ||
| Q2 25 | $27.0M | $28.6M | ||
| Q1 25 | $30.7M | $15.0M | ||
| Q4 24 | $48.4M | $39.2M | ||
| Q3 24 | $27.5M | $49.3M | ||
| Q2 24 | $23.9M | $42.2M | ||
| Q1 24 | $13.3M | $44.7M |
自由现金流EVCMRGEN
| Q4 25 | $21.0M | $17.6M | ||
| Q3 25 | $31.6M | $43.4M | ||
| Q2 25 | $26.5M | $21.5M | ||
| Q1 25 | $30.2M | $11.4M | ||
| Q4 24 | $48.2M | $33.6M | ||
| Q3 24 | $27.4M | $42.3M | ||
| Q2 24 | $23.3M | $37.4M | ||
| Q1 24 | $12.9M | $36.4M |
自由现金流率EVCMRGEN
| Q4 25 | 13.9% | 8.9% | ||
| Q3 25 | 21.4% | 23.0% | ||
| Q2 25 | 17.9% | 11.8% | ||
| Q1 25 | 21.2% | 6.8% | ||
| Q4 24 | 33.5% | 19.3% | ||
| Q3 24 | 19.5% | 27.3% | ||
| Q2 24 | 16.6% | 24.3% | ||
| Q1 24 | 9.4% | 24.0% |
资本支出强度EVCMRGEN
| Q4 25 | 0.2% | 4.1% | ||
| Q3 25 | 0.6% | 2.5% | ||
| Q2 25 | 0.3% | 3.9% | ||
| Q1 25 | 0.3% | 2.1% | ||
| Q4 24 | 0.2% | 3.2% | ||
| Q3 24 | 0.1% | 4.5% | ||
| Q2 24 | 0.5% | 3.1% | ||
| Q1 24 | 0.3% | 5.5% |
现金转化率EVCMRGEN
| Q4 25 | 3.52× | 1.93× | ||
| Q3 25 | 2.93× | 3.23× | ||
| Q2 25 | 3.31× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
RGEN
暂无分部数据
